BASIC AND CLINICAL STUDIES ON CEFODIZIME (THR-221)
スポンサーリンク
概要
- 論文の詳細を見る
We performed laboratory and clinical studies on cefodizime (THR-221), a new cephalosporin antibiotic.<BR>1. Antimicrobial activity<BR>The MICs of THR-221, latamoxef (LMOX), cefoperazone (CPZ), and cefotaxime (CTX) for 20 strains of <I>E. coli</I>, 20 of <I>Klebsiella</I> and 19 of <I>E. faecalis</I>, were determined according to the methods of the Japanese Society of Chemotherapy, and their antibacterial activities were compared.<BR>2. Clinical effect<BR>The clinical effect of THR-221 was studied in 5 patients, 1 with chronic bronchitis, 1 with bronchopneumonia, 2 with acute pyelonephritis and 1 with chronic cystitis. This antibiotic was administered to all patients at 1 g twice a day for 7-13 days.<BR>Clinical results were excellent in 2 cases, good in 2 and fair in 1 case. The clinical efficacy rate was 80%. No sideeffects or abnormal laboratory findings were observed in any cases.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.